Xiamen Amoytop Biotech Stock Hits Day Low Amid Price Pressure at CNY 60.88

Xiamen Amoytop Biotech Co. experienced a notable decline today, with the stock dropping by 4.79% and reaching an intraday low of CNY 60.88. This performance contrasts with the China Shanghai Composite, which saw a slight increase of 0.04% on the same day. Over the past week, Xiamen Amoytop has shown a modest gain of 1.78%, while its one-month performance stands at 2.79%. However, the stock has faced significant challenges over the past year, with a decline of 28.21%, compared to the China Shanghai Composite's gain of 3.56%. Year-to-date, the stock is down 26.05%, while the broader market has only decreased by 1.6%. Despite these recent setbacks, Xiamen Amoytop has reported positive results for the last 18 consecutive quarters, with net sales reaching a record high of CNY 1,216.02 million and an operating profit of CNY 472.2 million. The company maintains a strong return on equity of 34.50% and a competitive dividend yield of 1.06%. As a large-cap player in the pharmaceuticals and biotechnology sector, Xiamen Amoytop continues to navigate a challenging market landscape.